A Study of Nasal Glucagon in Participants With Type 1 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03339453|
Recruitment Status : Completed
First Posted : November 13, 2017
Results First Posted : September 23, 2019
Last Update Posted : September 23, 2019
|Study Design||Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: None (Open Label); Primary Purpose: Basic Science|
Diabetes Mellitus, Type 1
Drug: Nasal Glucagon
Drug: Intramuscular Glucagon
In each period, either 3 milligram (mg) nasal glucagon (NG) or 1 mg intramuscular (IM) Glucagon was administered.
After a wash-out period of at least 1 day (24 hours) from the first period (first visit), participants crossed over to the alternate glucagon treatment in period 2 (second visit).